Observational studyBMC pediatrics2025

A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China.

Xuedi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.